Pfizer Inc. (NYSE:PFE) Holdings Trimmed by Wrapmanager Inc.

Wrapmanager Inc. cut its holdings in Pfizer Inc. (NYSE:PFE) by 12.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,947 shares of the biopharmaceutical company’s stock after selling 3,173 shares during the quarter. Wrapmanager Inc.’s holdings in Pfizer were worth $661,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer during the third quarter valued at $30,000. Mizuho Securities Co. Ltd. purchased a new stake in Pfizer during the third quarter valued at about $34,000. VisionPoint Advisory Group LLC boosted its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. GoalVest Advisory LLC increased its position in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer during the fourth quarter valued at approximately $36,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.3 %

Shares of Pfizer stock traded down $0.07 during midday trading on Thursday, reaching $28.20. 47,806,405 shares of the company’s stock traded hands, compared to its average volume of 43,591,230. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The company’s 50 day simple moving average is $26.94 and its 200 day simple moving average is $28.12. The company has a market cap of $159.66 billion, a price-to-earnings ratio of -469.59, a price-to-earnings-growth ratio of 1.17 and a beta of 0.63.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The business’s revenue was down 19.5% compared to the same quarter last year. During the same period last year, the company earned $1.23 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 5.96%. Pfizer’s payout ratio is currently -2,799.53%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Morgan Stanley lifted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $36.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.